WO2025106626 - GENETICALLY ENGINEERED CELLS EXPRESSING C-X-C CHEMOKINE RECEPTOR TYPE 4, AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/106626
Publication Date
22.05.2025
International Application No.
PCT/US2024/055850
International Filing Date
14.11.2024
Title **
[English]
GENETICALLY ENGINEERED CELLS EXPRESSING C-X-C CHEMOKINE RECEPTOR TYPE 4, AND USES THEREOF
[French]
CELLULES GÉNÉTIQUEMENT MODIFIÉES EXPRIMANT UN RÉCEPTEUR DE CHIMIOKINE C-X-C DE TYPE 4, ET LEURS UTILISATIONS
Applicants **
CENTURY THERAPEUTICS, INC.
Inventors
MORSE, Barry
NASO, Michael, Francis
QUINN, Hillary
Priority Data
63/599,520
15.11.2023
US
63/569,849
26.03.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5431 | |
| EPO | Filing, Examination, Granting | 68756 | |
| Japan | Filing, Examination, Granting | 4162 | |
| South Korea | Filing, Examination, Granting | 6003 | |
| USA | Filing, Examination, Granting | 19690 |
Total:
104,042
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof that express C-X-C chemokine receptor type 4 (CXCR4). Also provided are uses of the CXCR4 positive iPSCs or derivative cells thereof for allogenic cell therapy.[French]
L'invention concerne des cellules souches pluripotentes induites (CSPi) génétiquement modifiées et des cellules dérivées de celles-ci qui expriment le récepteur de chimiokine C-X-C de type 4 (CXCR4). L'invention concerne également des utilisations des CSPi positives CXCR4 ou des cellules dérivées de celles-ci pour une thérapie cellulaire allogénique.